Last reviewed · How we verify
NCT03827265
Transcranial Magnetic Stimulation and Tobacco Use Disorder
NA trial testing repetitive transcranial magnetic stimulation (rTMS) in Tobacco Use Disorder in 60 participants. Completed in 19 August 2024.
19 August 2024
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | single |
| Primary purpose | other |
| Enrollment | 60 |
| Start date | 1 February 2019 |
| Primary completion | 19 August 2024 |
| Estimated completion | 19 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- repetitive transcranial magnetic stimulation (rTMS)
Conditions studied
- Tobacco Use Disorder — all drugs for Tobacco Use Disorder →
Sponsor
University of California, Los Angeles
Who can join
Adults 18 to 45, any sex, with Tobacco Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if brain stimulation using repetitive transcranial magnetic stimulation (rTMS) directed at different parts of the brain can decrease feelings of cigarette craving and symptoms of cigarette withdrawal, and also if men and women have different responses to rTMS. Participants will visit the University of California, Los Angeles (UCLA) five times: First, for in-person screening, then for four rTMS sessions, four three different brain regions. Everyone in the study will be assigned to all four treatment arms and they will take place in a random order. Before and after each rTMS session, a brief MRI will be performed, and participants will be asked to fill out questionnaires that describe how they are feeling.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Comparing neuromodulation targets to reduce cigarette craving and withdrawal: a randomized clinical trial.
Petersen N, Apostol MR, Jordan T, Ngo TDP, et al · · 2025 · cited 2× · PMID 40281039 · DOI 10.1038/s41386-025-02106-2 -
Illuminating posterior targets for TMS beyond the prefrontal cortex.
McCalley DM, Sanderson LL, Dowdle LT, Padula CB, et al · · 2025 · cited 1× · PMID 42145912 · DOI 10.1038/s44220-025-00433-3 -
ACNP 61<sup>st</sup> Annual Meeting: Poster Abstracts P541 - P809.
· 2022 · cited 1× · PMID 36456695 · DOI 10.1038/s41386-022-01486-z
Verify or expand the search:
- PubMed search for NCT03827265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of repetitive transcranial magnetic stimulation (rTMS)
Trials testing the same drug.
- NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
- NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
- NCT07249801 — Closed-loop rTMS-EEG During Visuomotor Integration. · NA · recruiting
- NCT06451835 — Evaluation of Response to a Course of Repetitive Transcranial Magnetic Stimulation Using Vocal Biomarkers · suspended
- NCT05542641 — T-mult: Exploring the Impact of TMS Induced Virtual Lesions on the Multimodal Brain Network and Cognition · NA · completed
Other recruiting trials for Tobacco Use Disorder
Currently open trials in the same condition.
- NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
- NCT06678672 — Contingency Management for Veteran Smokers Undergoing Major Elective Surgery · NA · recruiting
- NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
- NCT06798324 — tDCS Plus Varenicline for Smoking Cessation · Phase 4 · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03827265 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing